GO
Loading...

Enter multiple symbols separated by commas

Actavis Inc

More

  • US STOCKS-Wall St dips as investors edgy ahead of Fed meet Wednesday, 17 Jun 2015 | 12:57 PM ET

    *Fed statement at 2 p.m. ET; Yellen conference at 2:30 p.m.. *Apple weighs on Nasdaq, S&P; UnitedHealth biggest drag on Dow. The Fed statement will be followed by Chair Janet Yellen's news conference half an hour later.

  • *Fed statement at 2 p.m. ET; Yellen conference at 2:30 p.m.. The Fed statement is due at 2:00 p.m. ET, followed by Chair Janet Yellen's news conference half an hour later, with analysts expecting her to focus on signs the economy is recovering after a bumpy start to the year. "The Fed will send out another message which lays down the groundwork for a rate rise in August...

  • US stocks rise after Fed stands pat on rates Wednesday, 17 Jun 2015 | 10:23 AM ET

    Stocks edged higher Wednesday after the Federal Reserve reassured investors it was in no rush to raise interest rates from historically low levels. The central bank said that the economy is strengthening, but not enough for policymakers to signal an imminent rate hike. "This makes the market feel more confident," said Alan Rechtschaffen, financial advisor at...

  • NEW YORK— Shares of Synergy Pharmaceuticals jumped 47 percent before Wednesday's opening bell on encouraging, late-state study results for its constipation drug. If it reaches the market, plencantide would compete with Sucampo Pharmaceuticals Inc.' s and Takeda Pharmaceutical Co.' s drug Amitiza and Allergan Plc.' s Linzess. Shares of Shares of Synergy...

  • June 17- Wall Street was set to open little changed on Wednesday as investors were reluctant to add to positions ahead of a Federal Reserve statement that could provide hints on the timing of a rate hike. The Fed statement is due at 2:00 p.m. ET, followed by Chair Janet Yellen's news conference half an hour later, with analysts expecting her to focus on signs the...

  • NEW YORK— Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin". Kythera Biopharmaceuticals Inc. is preparing to launch its double chin treatment Kybella in the U.S., and the company is seeking approval in foreign markets as...

  • June 17- Botox-maker Allergan Inc said it would buy Kythera Biopharmaceuticals Inc in a cash-and-stock deal valued at about $2.1 billion, to expand its line of cosmetic treatments. The offer price of $75 per Kythera share represents a premium of 23.5 percent to the stock's Tuesday close. Buying Kythera will give Allergan access to Kybella, the first and only...

  • June 5- Orexigen Therapeutics Inc and partner Takeda Pharmaceutical Co Ltd said they had filed a lawsuit against Actavis Plc to block a generic version of diet-pill Contrave. The lawsuit, filed at a Delaware district court, alleges that Actavis has infringed patents on Orexigen and Takeda's weight-loss treatment. Actavis and Teva Pharmaceutical Industries...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday. The decision at the 2nd U.S. Circuit Court of Appeals is a win for New York State Attorney General Eric Schneiderman, who sued to block the switch, arguing that Actavis was...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. A three-judge panel at the 2nd U.S. Circuit Court of Appeals in New York upheld an order by U.S. District Robert Sweet in December requiring Actavis to keep the older drug, Namenda IR, on the...

  • May 14- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing. Warner Chilcott said the company and several of its employees in the sales organization received subpoenas in 2012 from the United...

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...

  • US STOCKS-Wall St mixed at open; energy shares fall Monday, 11 May 2015 | 10:27 AM ET

    *Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. Exxon Mobil shares fell 1.1 percent to $87.28.

  • *Rosetta soars as Noble Energy offers to buy company for $2 bln. *Zulily rises after Alibaba increases stake. "There will be some carry-over from the positive jobs report but not at the same magnitude," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.

  • May 11- Drugmaker Actavis Plc, which completed its $66 billion acquisition of Botox maker Allergan in March, reported a better-than-expected quarterly profit, helped by higher sales of its branded drugs in North America. Actavis forecast 2015 revenue of $20.5 billion to $21 billion on Monday. Actavis said first-quarter results included business from...

  • *Zulily shares jumped 18.4 percent to $15.75 in premarket trading, after Alibaba bought a 9 percent stake in the online retailer. Alibaba was down marginally at $86.73. *Actavis rose 3.1 percent to $302 after the drugmaker's revenue jumped almost 60 percent, helped by higher sales of its branded drugs in North America.

  • May 8- A U.S. judge on Friday dismissed a lawsuit filed by the city of Chicago in federal court against four drugmakers accused of promoting painkiller addiction through deceptive marketing, though the case will continue against Oxycontin maker Purdue Pharma LP. The companies dismissed from the lawsuit are Teva Pharmaceutical Industries Ltd, Johnson&...

  • May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The case, which began in 2000 in California state court, centers on a series of settlements in the late 1990 s under...

  • NEW YORK, May 4- Billionaire hedge fund manager David Einhorn, who often moves a stock simply by speaking its name, on Monday kicked off the year's most prominent investment conference by laying out a case against oil frackers, arguing these companies drill "lots and lots of holes" and burn through plenty of cash. Einhorn, who often unveils so-called short-bets...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...